NCT06289452View on ClinicalTrials.gov

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2029

Conditions
RetinoschisisRetinal DiseaseRetinal DegenerationEye Diseases
Interventions
GENETIC

IVB102 Injection

Gene transfer by intravitreal injection of the RS1 AAV vector

GENETIC

IVB102 Injection

Gene transfer by intravitreal injection of the RS1 AAV vector

GENETIC

IVB102 Injection

Gene transfer by intravitreal injection of the RS1 AAV vector

Trial Locations (1)

100142

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

lead

InnoVec Biotherapeutics Inc.

INDUSTRY